Abstract:Introduction SSRIs are the most prescribed psychiatric drug in the United States, with approximately 40% of patients reporting side effects to their provider (1,2). It is accepted that side effects of SSRIs may include sexual dysfunction, including decreased libido and anorgasmia (3,4). However, the safety of SSRIs on the functions of the genitourinary and reproductive systems in real-world settings remains unclear. Objective The aim of this study was to identify urinary and gynecologic adverse events associated with SSRIs using data from the FDA Adverse Events Reporting System (FAERS). Secondarily, we identify variability of adverse events across individual SSRIs. Methods A specialized software to analyze adverse events, OpenVigil 2.1, was used to query the FAERS data. We defined 445 search terms related to genitourinary and reproductive system related events. We performed disproportionality analysis to identify associations between search terms and SSRIs as a class, then each SSRI (fluoxetine, sertraline, paroxetine, escitalopram, citalopram). Subgroup analysis was performed to stratify adverse events by age. Results Adverse events related to SSRI usage include a variety of genitourinary and reproductive system related side effects, not limited to sexual dysfunction. Gynecologic bleeding, urinary retention, hypersexuality emerged as surprisingly statistically significant signals across females. Statistically significant adverse events related to sexual dysfunction were present up to age 60, with the strongest signals found in the 40-59 years age group. Urinary symptoms were most prevalent in the 0-18 years and over 60 years age group. Of the SSRIs, citalopram had the strongest association with sexual disorders and dysfunction. Conclusions In this study, we offer the most granular side effect profile of SSRIs related to the urinary and reproductive systems to date. While the pathophysiology of each adverse event remains unclear, an understanding of potential risks of these drugs is valuable in the management of patients taking SSRIs, particularly in the event of rare side effects that are often not associated with SSRI use. These are important considerations for clinical practice as side effects of SSRIs can impact treatment compliance and patient quality of life. References 1. Cascade EM, Kalali AM, Kennedy SHMF. Real-World Data on SSRI Antidepressant Side Effects. Psychiatry. 2009;16–8. 2. US National Library of Medicine. Mental Health Medications. National Institute of Mental Health. 2022. 3. Segraves RT. Sexual Dysfunction Associated with Antidepressant Therapy. Vol. 34, Urologic Clinics of North America. 2007. p. 575–9. 4. Rosen RCP, Lane RMM, Menza MM. Effects of SSRIs on Sexual Function: A Critical Review. J Clin Pharmacol. 1999;19(1):67–85. Disclosure No.

Patterns of SSRI Exposures Reported to the U.S. Poison Centers

Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System

Possible Sertraline-Induced Extrapyramidal Adverse Effects in an Adolescent.

Trends in antidepressant overdoses

Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014

Analysis of prescriptions of three selective serotonin reuptake inhibitors from a perspective of metabolic interactions

(100) Urinary and Gynecologic Adverse Events Associated with Ssri Use

Risk of Suicidal Behaviors and Antidepressant Exposure Among Children and Adolescents: A Meta-Analysis of Observational Studies

Drug–Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database

Psilocybin Exposures Reported to US Poison Centers: National Trends Over a Decade

National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis

Reproductive Toxicity Induced by Serotonin‐Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database

Suicidal antidepressant overdoses: A comparative analysis by antidepressant type

A large-scale observational comparison of antidepressants and their effects

Three safety indices for the fourteen most prescribed antidepressants in the US, 2013-2020

Pediatric ADHD Medication Exposures Reported to US Poison Control Centers

An atypical case of serotonin syndrome with normal dose of selective serotonin inhibitors: A case report.

Eye Disorders Associated with Selective Serotonin Reuptake Inhibitors: a Real-World Disproportionality Analysis of FDA Adverse Event Reporting System

Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database

Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database

Selective Serotonin Reuptake Inhibitor Prescribing Within An Integrated Pediatric Primary Care Behavioral Health Program